Cellectar Shares Surge on Promising Clinical Developments

The biotechnology sector is witnessing notable momentum in Cellectar Biosciences, with the company’s stock demonstrating substantial upward movement following significant clinical progress. Investor attention has intensified around Cellectar’s targeted radiopharmaceutical pipeline, particularly its lead candidates iopofosine I-131 and CLR 121225.

Recent regulatory recognition has provided substantial momentum for Cellectar. The U.S. Food and Drug Administration granted Rare Pediatric Disease designation to iopofosine I-131 for treating pediatric high-grade glioma that is inoperable, relapsed, or refractory. This designation highlights the therapy’s potential in addressing this challenging childhood cancer.

Supporting data from the Phase 1b CLOVER-2 trial revealed encouraging interim results:
* Patients receiving minimum total doses of 55 mCi Read more...